Connect with us

Technology

Kodiak Sciences Completes Enrollment in First Pivotal Cohort in the Phase 3 PEAK Trial of KSI-101 for Macular Edema Secondary to Inflammation and Reaffirms Topline Clinical Data Release Remains on Track for December 2026

Published

on

First pivotal cohort enrolled 300 subjects, with topline clinical data from 24-week primary endpoint on track for December 2026 releaseCompletion of enrollment in the second pivotal cohort evaluating 600 subjects across the PEAK and PINNACLE studies is expected in 4Q 2026, with topline clinical data release anticipated in 2Q 2027

PALO ALTO, Calif., Aug. 6, 2026 /PRNewswire/ — Kodiak Sciences Inc. (Nasdaq: KOD) today announced that it has completed enrollment of the first 300-patient cohort in its PEAK trial, supporting Pivotal Analysis 1 of the KSI-101 Phase 3 program in macular edema secondary to inflammation (“MESI”). Kodiak also reaffirmed its plan to release the topline data from Pivotal Analysis 1 in December 2026.

“We were pleased to complete this important enrollment milestone in early June , and we can now confidently plan for the topline data to be released in December 2026,” said Victor Perlroth, M.D., Chief Executive Officer of Kodiak. “Our data from the Phase 1b APEX study meaningfully increased our conviction in KSI-101’s potential to be a cornerstone therapy for MESI patients. The global registrational PEAK trial is the first pivotal test of that conviction, and we look forward to sharing topline data before the end of this year.”

“Pivotal Analysis 1 gives us the opportunity to evaluate KSI-101 in patients with more severe MESI across our global site footprint,” said J. Pablo Velazquez-Martin, M.D., Chief Medical Officer of Kodiak. “These are patients at high risk of losing meaningful vision, and the goal of treatment is not only to reduce inflammation but to dry the retina and improve vision without the toxicities and other limitations associated with today’s complex patchwork of systemic and ocular therapies. KSI-101 was designed for this clinical challenge, and we are grateful to the patients, investigators and study teams who have helped bring the program to this important milestone.”

“MESI encompasses a broad range of diseases resulting in a swollen macula and which are not attributable to other common causes of retinal edema such as wet AMD, diabetic macular edema and retinal vein occlusion. MESI represents a meaningful number of patients in my retina practice,” said David Eichenbaum, M.D., Director of Research at Retina Vitreous Associates of Florida and a principal investigator in the PEAK and PINNACLE clinical trials. “Many of these patients have experience with corticosteroid use and understand its limitations, including the risks of elevated intraocular pressure and cataract. I am encouraged by the data generated to date with KSI-101 in which the therapy appears to work well and to date is demonstrating a favorable safety profile. KSI-101 could open up treatment for MESI to many more patients and may meaningfully change the treatment paradigm for this diagnosis in retina practice in the years ahead. I’m thrilled to be on the leading edge of this program.”

About Macular Edema Secondary to Inflammation (MESI)

MESI is a heterogeneous group of diseases that clinically present with macular edema and visual impairment which are caused by a common pathophysiology of inflammation and blood retinal barrier disruption. The clinical presentation of retinal fluid and visual impairment is a mainstay in these patients, irrespective of the location of the inflammation inside of the eye (anterior, intermediate, posterior or all intraocular compartments) or the specific etiology (defined autoimmune associated, idiopathic, post-procedural, or inflammatory choroidal neovascularization).

Currently there are no available intravitreal biologic therapies addressing the spectrum of MESI diseases. Existing therapies remain limited by side effects and tolerability, underscoring the need for safer and more effective treatment options. MESI represents a new macular edema market segment separate from the established anti-VEGF market.

About KSI-101

KSI-101 is a novel, potent and high strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF for the treatment of MESI. Data from our dose-finding Phase 1b APEX study demonstrated robust anatomical and visual responses across MESI patients. More than half of patients achieved ≥15-letter gains in best corrected visual acuity, with additional benefit at higher dose levels. Rapid vision improvements and anatomical response were observed with 10-letter gains by Week 4 in top dose groups and OCT CST <325 microns achieved as early as Week 1 in top dose groups. Continued anatomical improvement was observed over time with >90% resolution of intraretinal (“IRF”) and subretinal fluid (“SRF”) by Week 8 and 20/25 Snellen visual acuity by Week 20. In top dose groups, ≥90% achieved complete absence of IRF and SRF, indicating retinal dryness and normalization of retinal architecture. KSI-101 also continued to be well tolerated with a favorable safety profile. The top two dose levels in APEX have been advanced into the Phase 3 pivotal studies, PEAK and PINNACLE. The PEAK and PINNACLE studies are actively enrolling.

About PEAK and PINNACLE

The PEAK and PINNACLE studies are superiority studies evaluating two dose levels of KSI-101 (5 mg and 10 mg) compared to sham treatment in patients with MESI. PEAK and PINNACLE are identical in study design with key differences in patient population. PEAK includes patients with more severe disease (moderate to severe macular edema and vision impairment) and PINNACLE includes patients with milder disease (mild macular edema and any vision impairment), as well as patients with moderate to severe macular edema with good vision. Together, PEAK and PINNACLE are designed to enroll complementary patient populations and to cover a wide spectrum of MESI patients.

Patients randomized to the KSI-101 treatment arms will receive fixed monthly dosing for 6 doses (from Day 1 to Week 20), with subsequent individualized dosing (up to monthly dosing) for 6 additional visits (Week 24 to Week 44). Patients in the sham arm will receive monthly sham dosing for 6 doses followed by sham PRN. The primary and key secondary endpoints will be evaluated at Week 24. PEAK and PINNACLE are now actively enrolling patients. Topline data readouts for Pivotal Analysis 1 (PEAK patients 1 – 300) and Pivotal Analysis 2 (PEAK patients 301 – 600 and PINNACLE patients 1 – 300) are expected in December 2026 and 2Q 2027, respectively.

About Kodiak Sciences Inc.

Kodiak Sciences (Nasdaq: KOD) is a pre-commercial retina-focused biotechnology company committed to researching, developing and commercializing transformative therapeutics. We are focused on bringing new science to the design and manufacture of next-generation retinal medicines to prevent and treat the leading causes of blindness globally. We are developing a portfolio of three late-stage clinical programs. Zenkuda™ (tarcocimab tedromer) has a BLA-ready profile in diabetic retinopathy, retinal vein occlusion and wet AMD, and, together with KSI-501, is being explored in the BLA-facing Phase 3 DAYBREAK wet AMD study, with topline data expected in September 2026. Zenkuda and KSI-501 target the $15 billion anti-VEGF market across retinal vascular diseases. KSI-101 is a bispecific protein being explored in two BLA-facing Phase 3 studies in Macular Edema Secondary to Inflammation (MESI). Topline data for Pivotal Analysis 1 (PEAK) are expected in December 2026 and Pivotal Analysis 2 (PEAK+PINNACLE) in 2Q 2027.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact and include statements regarding:  Kodiak’s plans to release topline data; Kodiak’s expectation regarding the timing of completion of enrollment in the PEAK and PINNACLE studies; Kodiak’s belief regarding KSI-101’s efficacy and safety profile based on data from the Phase 1b APEX study and in the PEAK and PINNACLE studies. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “could,” “expect,” “plan,” “believe,” “intend,” “pursue,” “anticipate,” and other similar expressions, among others. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that data observed to date in the Phase 1b APEX study or in the ongoing PEAK and PINNACLE studies may not continue or persist, or may not be replicated in later analyses or in a larger or more diverse patient population; the risk that KSI-101 may not achieve the primary or key secondary endpoints in the PEAK or PINNACLE studies or may not do so on the anticipated timeline; the risk that cessation, modification, or delay of the PEAK or PINNACLE studies, or of Kodiak’s development of KSI-101 or any other product candidate, may occur; the risk that KSI-101 may not be successfully developed, approved, or commercialized; the risk that Kodiak’s research and development efforts and ability to advance product candidates into later stages of development may fail; adverse conditions in the general domestic and global economic markets, which may significantly impact Kodiak’s business and operations, including its clinical trial sites, as well as the business or operations of its manufacturers, contract research organizations, or other third parties with whom Kodiak conducts business; as well as the other risks identified in the section entitled “Risk Factors” in Kodiak’s most recent Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in Kodiak’s subsequent filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and Kodiak undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Readers are cautioned not to place undue reliance on such forward-looking statements.

 

 

View original content:https://www.prnewswire.com/news-releases/kodiak-sciences-completes-enrollment-in-first-pivotal-cohort-in-the-phase-3-peak-trial-of-ksi-101-for-macular-edema-secondary-to-inflammation-and-reaffirms-topline-clinical-data-release-remains-on-track-for-december-2026-302844806.html

SOURCE Kodiak Sciences Inc.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Equinix Partners with Central Georgia Electric Membership Corporation to Protect Ratepayers

Published

on

By

New contract model has Equinix cover full costs of transmission and power infrastructure, backed by a 20-year take-or-pay agreement for the Hampton, Ga. project

REDWOOD CITY, Calif., Aug. 6, 2026 /PRNewswire/ — Equinix, Inc. (Nasdaq: EQIX), the world’s digital infrastructure company® and regional, not-for-profit utility cooperative Central Georgia Electric Membership Corporation (CGEMC) announced a new partnership to protect Hampton, Ga. ratepayers and surrounding communities. In keeping with the company’s commitment to President Trump’s Ratepayer Protection Pledge, Equinix will cover all grid infrastructure improvements and fund new transmission and power capacity needed to support growth and improve regional grid reliability and affordability for decades to come.

“The United States needs bold infrastructure investment, and we’re proud to support efforts to drive economic growth and cutting-edge innovation while protecting ratepayers every step of the way,” said Equinix Senior Vice President of Global Energy Adrian Anderson. “Our investment in Georgia shows the power of this idea in action. We’ve covered costs through an agreement that is locked in for more than 20 years, giving the community the certainty they can count on.”

The agreement outlines that Equinix will cover any financial obligations CGEMC takes on for grid upgrades and new generation supply for the Hampton project, including unforeseen or shifting costs, guaranteeing that ratepayers are never left to pay costs associated with the project. Equinix will also supply up-front payments for the initial grid upgrade costs, covering a new high-voltage substation and two new high-voltage transmission lines, and early site assessments, modeling and engineering work. To lock in these provisions, Equinix and CGEMC have entered a 20-year “take-or-pay” style contract, meaning Equinix will pay 100% of CGEMC’s costs for serving the contracted demand of the Hampton facility.

“This agreement with Equinix is a model for how utilities and data centers can come together to meet new power requests responsibly and fulfill President Trump’s Ratepayer Protection Pledge,” said CGEMC President & CEO George L. Weaver. “With this agreement in place, CGEMC can improve the reliability of our system, deliver economic opportunity to the region, and ensure large new customers are paying their fair share.”

Equinix has been part of the metro Atlanta community for more than 15 years. Through the Hampton project, it will contribute up to $20 million annually in property tax revenue to the community, funding schools and emergency services, and will create more than 990 jobs from across the local economy. In 2023 alone, its presence contributed $23 million to household incomes in Atlanta from employment and value chain spend. The project will also extend Equinix’s Pathways to Tech program to the region, which educates local students about careers in the data center industry. In 2025, Equinix hosted more than 60 data center tours and education sessions to engage over 1,800 students across 32 locations.

“Companies like Equinix are helping our state and nation stay at the forefront of innovative technology,” said Georgia Governor Brian Kemp. “By partnering with Central Georgia EMC in this way, they are making key investments in the local community and protecting ratepayers at the same time.”

“Hampton is proud to welcome this kind of responsible, long-term investment in our community,” said Mayor Ann Tarpley. “Equinix’s commitment to covering these infrastructure costs upfront means our residents and local businesses get the benefits of growth, new jobs, stronger schools, and a more reliable grid, without carrying the financial burden. This is exactly the kind of partnership that helps a city like ours grow the right way.”

This agreement builds off Equinix’s partnerships with PG&E in San Jose, Calif. and ComEd in Northern Illinois and can serve as a model for other projects across the country. 

Additional Resources

Equinix Together: Our five principles of community investmentBlog: We’re not just building data centers. We’re building communities.

About Equinix
Equinix, Inc. (Nasdaq: EQIX) shortens the path to boundless connectivity anywhere in the world. Its digital infrastructure, data center footprint and interconnected ecosystems empower innovations that enhance our work, life and planet. Equinix connects economies, countries, organizations and communities, delivering seamless digital experiences and cutting-edge AI—quickly, efficiently and everywhere.

Forward-Looking Statements
This press release contains forward-looking statements that involve risks and uncertainties. Actual results may differ materially from expectations discussed in such forward-looking statements. Factors that might cause such differences include, but are not limited to, risks to our business and operating results related to the current inflationary environment; foreign currency exchange rate fluctuations; stock price fluctuations; increased costs to procure power and the general volatility in the global energy market; the challenges of building and operating IBX® and xScale® data centers, including those related to sourcing suitable power and land, and any supply chain constraints or increased costs of supplies; the challenges of developing, deploying and delivering Equinix products and solutions; unanticipated costs or difficulties relating to the integration of companies we have acquired or will acquire into Equinix; a failure to receive significant revenues from customers in recently built out or acquired data centers; failure to complete any financing arrangements contemplated from time to time; competition from existing and new competitors; the ability to generate sufficient cash flow or otherwise obtain funds to repay new or outstanding indebtedness; the loss or decline in business from our key customers; risks related to our taxation as a REIT; risks related to regulatory inquiries or litigation; and other risks described from time to time in Equinix filings with the Securities and Exchange Commission. In particular, see recent and upcoming Equinix quarterly and annual reports filed with the Securities and Exchange Commission, copies of which are available upon request from Equinix. Equinix does not assume any obligation to update the forward-looking information contained in this press release.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/equinix-partners-with-central-georgia-electric-membership-corporation-to-protect-ratepayers-302844373.html

SOURCE Equinix, Inc.

Continue Reading

Technology

Disrupting Startup Failure Curve: Why Money and Skills Alone Are Not Enough

Published

on

By

On Disruption Interruption, Sean Reel explains why accelerators that focus on capital and training can miss the assumptions driving business failure. Ignite Bermuda uses enablement, minimum viable product (MVP) testing, and human-centered AI tools to help entrepreneurs identify barriers and learn faster.

TAMPA BAY, Fla., Aug. 6, 2026 /PRNewswire/ — Only 57.3% of U.S. business establishments born in 2018 were still operating five years later, according to the U.S. Bureau of Labor Statistics. Yet many accelerator models still treat failure as a normal cost of entrepreneurship instead of asking why businesses with capital, skills, and training continue to collapse. On this episode of Disruption Interruption, host Karla Jo Helms (KJ) speaks with Sean Reel, Executive Director of Ignite Bermuda, about why capital and training cannot rescue a company based on untested assumptions. Reel argues that founders need more than funding and education; they need a way to identify barriers before they spend valuable resources. “If you gave them the skills and the money, they would still fail,” Reel says.

The Accelerator Model Misses the Real Problem

For Reel, the broken part of the accelerator model is not education. Many programs provide training, tools, capital, and access, but still fail to change the founders’ underlying assumptions. The result is that entrepreneurs may become better prepared to execute a plan that was flawed from the start.

That problem does not stop with startups. Reel argues that midmarket and large companies are now facing the same pressure to rethink how they test ideas, protect resources, and respond to disruption. “What do we need to do today to innovate faster than we’ve ever innovated before?” he says. In his view, the lesson is to “take everybody on an entrepreneurial journey,” where failure is not treated as collapse, but as the place where learning happens.

Too many companies still spend heavily before they know whether the market will support the idea. Reel points to the minimum viable product (MVP), as a way to challenge that habit. “MVPs are about taking the smallest amount of money, smallest amount of time, and testing an assumption,” he says.

Building People Who Build Businesses

Instead of a traditional coaching model that tells founders what to do, Ignite Bermuda uses an enablement model that helps entrepreneurs reach the answers themselves. “I won’t tell you what to do,” he says. “I’ll guide you to the self-awareness where you can make your own decisions.”

That approach has helped the company defy the standard failure curve. Reel says the organization has reached an 80% success rate while supporting 600 businesses, creating 250 jobs, and adding about $10 million to Bermuda’s local gross domestic product each year. In one case, he describes working with an entrepreneur who believed she needed to grow from $7,000 to $10,000 a month before leaving her job. After being asked what problem she was solving and for whom, she repositioned the business and generated $70,000 in seven days.

The accelerator is applying the same logic to Spark AI, a small language model built around Bermuda-specific knowledge and the organization’s enablement model. The goal is not to let AI tell founders what to do, but to help them ask better questions. “It’s not AI. It’s not artificial,” Reel says. “It’s just another tool, but if you don’t put the human factor in, good luck.”

Ignite Bermuda’s mission is broader than startup formation. Reel says the organization has helped build companies, save struggling businesses, and support entrepreneurs solving local problems, from health monitoring to affordable funerals. But the core output is human capability. “We’re not building great businesses,” he says. “We’re building great people who will build great businesses.”

Links

Disrupting the AI Hype: Building Tech for Real-World Economic Survival with Sean Reel

Disruption Interruption is the podcast where you will hear from today’s biggest Industry Disruptors. Learn what motivated them to bring about innovation and how they overcame opposition to adoption.

https://omny.fm/shows/disruption-interruption/disrupting-the-ai-hype-building-tech-for-real-world-economic-survival-with-sean-reel

LinkedIn: https://www.linkedin.com/in/seanreeluk 
Company Website: http://www.ignitebermuda.com 

About Disruption Interruption™
Disruption is happening on an unprecedented scale, impacting all manner of industries — MedTech, Finance, IT, eCommerce, shipping, logistics, and more — and COVID has moved their timelines up a full decade or more. But WHO are these disruptors and when did they say, “THAT’S IT! I’VE HAD IT!”? Time to Disrupt and Interrupt with host Karla Jo “KJ” Helms, veteran communications disruptor. KJ interviews bad asses who are disrupting their industries and altering economic networks that have become antiquated with an establishment resistant to progress. She delves into uncovering secrets from industry rebels and quiet revolutionaries that uncover common traits — and not-so-common — that are changing our economic markets… and lives. Visit the world’s key pioneers that persist to success, despite arrows in their backs at www.disruption-interruption.com.

About Sean Reel
Sean Reel is the executive director of Ignite Bermuda, an entrepreneurship ecosystem and accelerator focused on helping founders build stronger businesses through mindset, enablement and practical testing. Over seven years, he has helped Ignite support 600 businesses, create 250 jobs and contribute about $10 million annually to Bermuda’s local economy. Reel is also an entrepreneur working on ventures including Spark AI and Smart Hydration, and his work centers on helping founders, companies and communities use limited time, money and resources more effectively.

About Karla Jo Helms
Karla Jo Helms is the Chief Evangelist and Anti-PR® Strategist for JOTO PR Disruptors™. Karla Jo learned firsthand how unforgiving business can be when millions of dollars are on the line — and how the control of public opinion often determines whether one company is happily chosen, or another is brutally rejected. Being an alumnus of crisis management, Karla Jo has worked with litigation attorneys, private investigators, and the media to help restore companies of goodwill into the good graces of public opinion — Karla Jo operates on the ethic of getting it right the first time, not relying on second chances and doing what it takes to excel. Helms speaks globally on public relations, how the PR industry itself has lost its way, and how, in the right hands, corporations can harness the power of Anti-PR to drive markets and impact market perception.

References

U.S. Bureau of Labor Statistics. (2024). Business Employment Dynamics twentieth anniversary! bls.gov/spotlight/2024/business-employment-dynamics-twentieth-anniversary/U.S. Bureau of Labor Statistics. (2024, March 4). 1-year survival rates for new business establishments by year and location. bls.gov/opub/ted/2024/1-year-survival-rates-for-new-business-establishments-by-year-and-location.htm

Media Inquiries:
Karla Jo Helms
JOTO PR™
727-777-4629

View original content to download multimedia:https://www.prnewswire.com/news-releases/disrupting-startup-failure-curve-why-money-and-skills-alone-are-not-enough-302844079.html

SOURCE Disruption Interruption

Continue Reading

Technology

Pickering Introduces LXI High-Current Switching Family for Signals up to 80 A and 300 V

Published

on

By

New 60-191 family combines high-current power switching and low-current sense switching in a compact 4U form factor

TEWKSBURY, Mass., Aug. 6, 2026 /PRNewswire/ — Pickering Interfaces, a leading supplier of modular signal switching and simulation solutions for electronic test and verification, has introduced the 60-191 LXI high current & sense SPST switching family. The company’s highest-current switching products to date, the new family can switch signals up to 80 A and 300 V while simplifying distribution, sequencing, and management of multiple high-current power supplies in automated test systems.

The 60-191 family is available in four standard configurations, combining up to twenty 40 A and four 80 A hermetically sealed SPST-NO contactors with a complementary number of 1 A SPST relays for sense lines. High-current and sense-line connections are via standard front-panel screw-terminal connections. Custom relay combinations and alternative connector options may be requested.

Installed between multiple high-current power supply units (PSUs) and a device or system under test, each unit can programmatically connect and disconnect each PSU’s positive and negative outputs and their associated high- and low-sense lines. Engineers can control every relay independently or operate two high-current and two low-current relays as a group with a single command, simplifying the switching of the four connections commonly used by a PSU.

“High-current switching in automated test systems is often implemented as a custom assembly using contactors and digital output modules,” said Steven Edwards, Head of Product Management at Pickering. “The 60-191 family provides fully tested, easily maintainable LXI alternatives in standard 4U enclosures, with the switching capacity, control features, and software support needed to integrate high-current supplies more quickly.”

Each unit includes a sequencing service that can store up to 5,000 predefined switching sequences and execute them through software or configurable hardware triggers. By storing sequences within the LXI controller, the units can reduce host transactions and system latency. Front-panel LEDs indicate switch status to simplify programming and debugging, while relay cycle counting supports preventive maintenance and balances usage across available paths.

The 60-191 units are controlled through an LXI 1.5-compliant 1000Base-T Ethernet interface using an API or built-in soft front panel. IVI and direct I/O drivers support Windows and Linux and common development environments, including LabVIEW, Python, C/C++, C#, MATLAB, and Simulink.

Typical applications include EV battery and high-drain automotive electronics testing, fuel-cell and hydrogen-electrolysis research, solar inverter and energy-storage testing, aerospace development, and functional or production testing of high-current power supplies.

All four standard configurations include a three-year warranty and Pickering’s guaranteed long-term product support. For product details, availability and local sales contacts, visit www.pickeringtest.com.

About Pickering Interfaces
Pickering Interfaces designs and manufactures modular signal switching and simulation products for electronic test and verification. Its PXI, LXI, and PCI solutions are used in test systems worldwide across automotive, aerospace and defense, energy, industrial, communications, medical, and semiconductor applications. 

View original content to download multimedia:https://www.prnewswire.com/news-releases/pickering-introduces-lxi-high-current-switching-family-for-signals-up-to-80-a-and-300-v-302843962.html

SOURCE Pickering Interfaces

Continue Reading

Trending